Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Current Liabilities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Total Current Liabilities for 3 consecutive years, with $36.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 18.4% to $36.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $36.0 million, a 18.4% decrease, with the full-year FY2024 number at $40.7 million, down 27.67% from a year prior.
  • Total Current Liabilities was $36.0 million for Q3 2025 at Inhibrx Biosciences, down from $38.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $56.3 million in Q4 2023 to a low of $36.0 million in Q3 2025.
  • A 3-year average of $42.7 million and a median of $40.7 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: fell 27.67% in 2024, then dropped 0.29% in 2025.
  • Inhibrx Biosciences' Total Current Liabilities stood at $56.3 million in 2023, then dropped by 27.67% to $40.7 million in 2024, then dropped by 11.65% to $36.0 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Total Current Liabilities are $36.0 million (Q3 2025), $38.9 million (Q2 2025), and $43.6 million (Q1 2025).